Justin M. Balko, PharmD, PhD, on Chemotherapy Plus Immunotherapy for Early-Stage Triple-Negative Breast Cancer

Posted: Friday, December 20, 2024

Justin M. Balko, PharmD, PhD, of Vanderbilt-Ingram Cancer Center, briefly discusses risk management and the various biomarkers under study when using a combination of chemotherapy and immunotherapy for patients with early-stage triple-negative breast cancer.

---